All questions
Guidelines: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
1 question · 2 sources
Questions that apply to every indication of Kisqali are on Kisqali (ribociclib), all indications.
Guidelines
What do NCCN guidelines recommend for Kisqali in metastatic breast cancer?
Note: The first six passages are from the NCCN clinical flashcard (dated July 2025) that the expert guidelines page links, which reproduces NCCN Guidelines for Breast Cancer Version 4.2025 for ER- and/or PR-positive, HER2-negative recurrent unresectable or stage IV disease. The guideline lists other CDK4/6 inhibitor combinations in the same regimen lists. The last two passages are from the expert guidelines page, which cites Version 6.2026 (accessed July 30, 2026).